Posts
Est. 2026 · Pennsylvania
The Caucus
and the Standard
How the Industry Maintains the Rules It Operates Under
The Plasma Protein Therapeutics Association writes safety standards, funds the research that validates those standards, grows a Congressional caucus that defends them, and participates in the FDA guidance process that codifies them. This is not corruption. It is architecture. The insulation layer, examined up close.
Members
Octapharma · Kedrion
Collection + Fractionation
Caucus
Guidance
Association · Industry body
IQPP · QSEAL · Lobbying
Evidence
Access
Congress
21 CFR · Appropriations
Plasma Caucus (40+ members)
Regulatory capture is a specific concept with a specific meaning. It does not require bribery, fraud, or explicit coordination. It describes a structural condition in which the regulatory apparatus governing an industry comes to serve the interests of that industry more reliably than it serves the public interest the apparatus was designed to protect. The mechanism is proximity, expertise asymmetry, and the slow drift of institutional priorities that comes when the regulated party is the most consistent, best-resourced, and most knowledgeable participant in the regulatory process.
The plasma industry offers a case study in how this works in practice — not through scandal, but through the ordinary operation of institutional relationships conducted over decades. The Plasma Protein Therapeutics Association, the industry's primary trade and lobbying body, has built a relationship with FDA, with Congress, and with the academic research infrastructure that makes it simultaneously the primary subject of regulation and the primary architect of the standards by which it is regulated.
This post maps that relationship. Not to allege corruption — the individuals involved are, in many cases, acting in good faith. But good faith is not the same as independence. And the question FSA asks is not whether people are corrupt. It is what the structure produces.
The most durable form of regulatory influence is not the kind that shows up in an investigation. It is the kind that becomes the standard. Once the industry's preferred framework is codified as regulation, the work of maintenance is invisible. The standard simply exists.
PPTA — the Plasma Protein Therapeutics Association — is the industry organization representing plasma collection companies and fractionators. Its members include CSL, Grifols, Takeda/BioLife, Octapharma, and Kedrion — the five firms that collectively control the vast majority of global plasma fractionation capacity. PPTA functions simultaneously as a lobbying organization, a standard-setting body, a research funder, and a liaison between the industry and its regulators.
The standard-setting function is the most structurally significant. PPTA operates the International Quality Plasma Program (IQPP), which establishes quality and safety standards for source plasma collection that supplement — and in practice, fill gaps in — FDA requirements. IQPP certification is effectively required for commercial viability: major fractionators will not accept plasma from non-IQPP-certified collection centers. This means the industry has created a private standard-setting architecture that operates alongside federal regulation, is controlled by the industry's own association, and shapes collection practices in ways that FDA oversight alone does not reach.
The central safety question underlying the blood economy is this: what are the long-term health effects of donating plasma up to 104 times per year? The FDA's frequency and volume limits are premised on the claim that this level of extraction is safe for healthy donors when monitored appropriately. That claim rests substantially on research. The question FSA asks is: who produced that research, and what did they stand to gain from its conclusions?
The answer is consistent. The major studies cited in defense of current FDA frequency limits are predominantly funded by PPTA member companies, conducted using methodologies the industry has advocated for, and published in journals where industry-academic collaboration in this field is standard. The methodology most commonly employed — the SF-36 self-reported health survey — measures how donors say they feel, not what longitudinal physiological data shows. Independent, long-term cohort studies with objective health outcomes are sparse. The evidentiary basis for FDA's safety framework is built primarily on research the industry paid for.
Limited — largely absent
The pattern is not exceptional. Industry-funded research is standard across pharmaceutical and medical device sectors. But it matters here in a specific way: the primary constituency whose interests are at stake — repeat donors, predominantly low-income — has no institutional voice in the research process. The industry funds the studies. The FDA reviews the studies. The donors are the subjects of the studies. They are not participants in designing them.
Self-reported health surveys are methodologically appropriate for certain research questions. They are not appropriate as the primary evidentiary basis for frequency limits governing a biological extraction performed on economically vulnerable populations up to 104 times annually. The choice to rely on self-report rather than objective longitudinal physiological data is not a neutral methodological decision. It is a choice that consistently produces favorable findings. The structure of the research mirrors the structure of the industry: both are optimized for supply continuity.
The Congressional Plasma Caucus is a bipartisan legislative working group dedicated to plasma supply issues. In 2025, PPTA and its member companies grew the caucus from approximately twenty-six to twenty-nine members to more than forty members — a significant institutional expansion achieved through a sustained engagement program including fly-in visits to Washington, briefings at the Rayburn House Office Building, and educational sessions connecting member company representatives with legislative staff and members of Congress.
The caucus is not a corrupt institution. Congressional caucuses are a normal feature of the legislative landscape — there are caucuses for every industry, interest group, and constituency. But the caucus performs a specific function in the blood economy's insulation architecture: it converts supply chain arguments into political ones, building a constituency of legislators whose engagement with plasma policy is mediated entirely by the industry that organized the caucus and populated its briefings.
The briefing content presented to caucus members and their staff is produced by the industry. Patient access arguments — the genuine reality that disrupting plasma supply harms people who depend on immunoglobulin therapy — are prominently featured. The labor economics of the donor base, the siting methodology, the self-reported safety data, and the border visa litigation are not the frame through which legislators encounter plasma policy. The caucus mediates the frame.
PPTA's relationship with FDA is formally collaborative. The association participates in FDA's Center for Biologics Evaluation and Research (CBER) liaison meetings, contributes to guidance document development, submits comments on proposed rules, and provides data used in regulatory assessments. This is not unusual — regulated industries routinely engage with their regulators. The FDA actively seeks industry input because industry possesses technical knowledge that the agency, with its limited resources, cannot independently generate.
The asymmetry this creates is structural. FDA's career staff in biologics regulation number in the hundreds. PPTA's member companies collectively employ thousands of technical and regulatory affairs professionals whose full-time work is understanding and shaping the regulatory environment. When FDA develops guidance on donor frequency limits, protein monitoring protocols, or deferral criteria, the most technically sophisticated input it receives comes from the industry whose business model depends on the outcome of that guidance.
What does a congressional briefing on plasma policy look like? The following is a composite representation, drawn from publicly available PPTA advocacy materials, congressional testimony records, and industry communications. It illustrates the framing through which legislators encounter the blood economy's architecture.
The United States is the world's leading supplier of plasma-derived medicines, providing approximately 70% of the global supply of immunoglobulins, clotting factors, and albumin. These medicines are essential for patients with primary immunodeficiency, hemophilia, and other serious conditions for which no alternative treatment exists.
American plasma donors — who voluntarily choose to donate and are compensated for their time — make this life-saving supply possible. The US system is the most regulated and rigorously screened in the world. FDA's Center for Biologics Evaluation and Research maintains comprehensive oversight of collection, testing, and manufacturing.
Any disruption to the US plasma supply — whether through regulatory changes, trade restrictions, or border policy — would have immediate and serious consequences for patients who depend on these medicines. The Congressional Plasma Caucus plays a vital role in ensuring that policymakers understand the stakes of plasma supply policy decisions.
FSA Analysis: Trium Publishing House · The Blood Economy · Post V
Every sentence in that document is defensible. The US does supply seventy percent of global plasma. The medicines are essential. The donors are not legally coerced. The system is regulated. Patient harm from supply disruption is a real risk.
What the document does not contain: the siting methodology, the poverty demographics, the self-report evidentiary basis for safety limits, the border visa litigation, the margin structure, or any acknowledgment that the industry wrote the document being used to shape the policy that governs it. The insulation layer, in its most refined form, is simply an accurate description of some things, in a frame that makes other things invisible.
Regulatory capture does not require anyone to act in bad faith. FDA officials who accept PPTA-funded research as the evidentiary basis for safety guidance are not corrupt — they are using the best available data in a resource-constrained environment. Congressional staff who attend PPTA briefings and form views about plasma policy are not corrupt — they are doing their jobs with the information available to them. PPTA representatives who present their industry's case effectively are not corrupt — they are performing the function trade associations are designed to perform.
What the structure produces, through the aggregate operation of these individually defensible actions, is a regulatory environment in which the primary beneficiary of permissive standards is also the primary participant in setting those standards, the primary funder of the research that validates them, and the primary organizer of the political constituency that defends them against challenge. The donor — who bears the physical cost of those standards and has no institutional seat at any of these tables — is represented in the process only by the industry that depends on their continued participation.
Post VI will move from domestic institutional architecture to international moral posture. The European nations that prohibit paid plasma domestically while importing it from the United States have built their own insulation layer — one that allows the ethical critique of the American system to coexist with absolute dependency on its output.
Next · Post VI · The European Alibi — EU prohibition as moral insulation for importing nations. The ethics are domestic. The dependency is global.
No comments:
Post a Comment